Cancers 2010, 2(2), 885-912; doi:10.3390/cancers2020885
Review

The Evolution of Biomarkers in Thyroid Cancer—From Mass Screening to a Personalized Biosignature

Division of Endocrine Surgery, University of California San Francisco, 1600 Divisadero St, C-347, Box 1674, San Francisco, CA 94143, USA RHG and EJM contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 26 March 2010; in revised form: 10 May 2010 / Accepted: 19 May 2010 / Published: 20 May 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
PDF Full-text Download PDF Full-Text [255 KB, uploaded 20 May 2010 12:07 CEST]
Abstract: Thyroid cancer is the most common malignancy of the endocrine system. The diagnosis of thyroid nodules, made by neck examination and ultrasonography, is a common event occurring in over 50% of the patient population over the age of 50. Yet, only 5% of these patients will be diagnosed with cancer. Fine needle aspiration biopsy is the gold standard for diagnosing thyroid nodules. However, 10–15% of these biopsies are inconclusive, ultimately requiring a diagnostic thyroid lobectomy. Consequently, research in thyroid biomarkers has become an area of active interest. In the 40 years since calcitonin was first described as the biomarker for medullary thyroid cancer, new biomarkers in thyroid cancer have been discovered. Advances in genomic and proteomic technologies have defined many of these novel thyroid biomarkers. The purpose of this article is to provide a comprehensive literature review of how these biomarkers have evolved from simple screening tests into a complex array of multiple markers to help predict the malignant potential and genetic signature of thyroid neoplasms.
Keywords: thyroid cancer; biomarker; biological marker; molecular marker; tumor marker; molecular pathways; epigenetics; serum based biomarkers; genomics; proteomics

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Grogan, R.H.; Mitmaker, E.J.; Clark, O.H. The Evolution of Biomarkers in Thyroid Cancer—From Mass Screening to a Personalized Biosignature. Cancers 2010, 2, 885-912.

AMA Style

Grogan RH, Mitmaker EJ, Clark OH. The Evolution of Biomarkers in Thyroid Cancer—From Mass Screening to a Personalized Biosignature. Cancers. 2010; 2(2):885-912.

Chicago/Turabian Style

Grogan, Raymon H.; Mitmaker, Elliot J.; Clark, Orlo H. 2010. "The Evolution of Biomarkers in Thyroid Cancer—From Mass Screening to a Personalized Biosignature." Cancers 2, no. 2: 885-912.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert